Evidence map›Paper›PMID 35557035›Full record

ReviewJournal of gynecologic oncology2022

Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052).

Hiroshi Asano, Katsutoshi Oda, Kosuke Yoshihara, Yoichi M Ito, Noriomi Matsumura, Muneaki Shimada, Hidemichi Watari, Takayuki Enomoto

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of gynecologic oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Hiroshi Asano *Department of Obstetrics and Gynecology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.ORCID 0000-0002-1033-3920
Katsutoshi Oda *Division of Integrative Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-2468-9573
Kosuke YoshiharaDepartment of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.ORCID 0000-0002-2254-3378
Yoichi M ItoData Science Center, Promotion Unit, Institute of Health Science Innovation for Medical Care, Hokkaido University Hospital, Sapporo, Japan.ORCID 0000-0001-5073-0827
Noriomi MatsumuraDepartment of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Osaka, Japan.ORCID 0000-0002-4512-7975
Muneaki ShimadaDepartment of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai, Japan.ORCID 0000-0003-1826-6723
Hidemichi WatariDepartment of Obstetrics and Gynecology, Hokkaido University Graduate School of Medicine, Sapporo, Japan. watarih@med.hokudai.ac.jp.ORCID 0000-0002-4189-6187
Takayuki EnomotoDepartment of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.ORCID 0000-0003-4538-5541
Hokkaido University · JPNiigata University · JPHokkaido University Hospital · JPKindai University · JPThe University of Tokyo · JPTohoku University · JP

Funding

Takeda Pharmaceutical Company
6 · The paper itself

Abstract

backgroundPoly (adenosine diphosphate)-ribose polymerase (PARP) inhibitors for tumors with homologous recombination deficiency (HRD), including pathogenic mutations in

methodsJGOG2052 is a single-arm, open-label, multi-center, phase 2 clinical trial to evaluate the efficacy and safety of niraparib monotherapy for a recurrent or persistent rare fraction of gynecologic malignancies with

trial registrationJapan Primary Registries Network (JPRN) Identifier: jRCT2031210264.

Indexed as

Genital Neoplasms, FemaleOvarian NeoplasmsClinical Trials, Phase II as TopicFemaleHomologous RecombinationHumansIndazolesPiperidinesIndazolesniraparibPiperidinesGeneGynecologic NeoplasmsHomologous Recombination RepairLeiomyosarcomaMutationPoly(ADP-ribose) Polymerase Inhibitors

Identifiers

PMID35557035
PMCPMC9250862
OpenAlexW4280577441

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.